Abstract
Laser in situ keratomileusis (LASIK) articles published between 2008 and 2015 that contain clinical outcomes data were reviewed and graded for quality, impression, and potential bias. All 97 relevant articles (representing 67 893 eyes) provided a positive or neutral impression of LASIK. Industry bias was not evident. The aggregate loss of 2 or more lines of corrected distance visual acuity was 0.61% (359/58 653). The overall percentage of eyes with uncorrected distance visual acuity better than 20/40 was 99.5% (59 503/59 825). The spherical equivalent refraction was within ±1.0 diopter (D) of the target refraction in 98.6% (59 476/60 329) of eyes, with 90.9% (59 954/65 974) within ±0.5 D. In studies reporting patient satisfaction, 1.2% (129/9726) of patients were dissatisfied with LASIK. Aggregate outcomes appear better than those reported in summaries of the safety and effectiveness of earlier laser refractive surgery systems approved by the U.S. Food and Drug Administration. Modern results support the safety, efficacy, and patient satisfaction of the procedure. Financial Disclosure Proprietary or commercial disclosures are listed after the references.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1224-1234 |
| Number of pages | 11 |
| Journal | Journal of cataract and refractive surgery |
| Volume | 42 |
| Issue number | 8 |
| DOIs | |
| State | Published - 2016 |
Bibliographical note
Funding Information:Dr. Donnenfeld is a consultant to Acufocus, Inc., Allergan, Inc., Alcon Laboratories, Inc., Abbott Medical Optics, Inc., Aquesys, Inc., Bausch & Lomb, Beaver-Visitec International, Carl Zeiss Meditec AG, Elenza, Inc., Glaukos Corp., Icon Bioscience, Inc., Kala Eyewear, Katena Products, Inc., Lacriscience, Mati Therapeutics, Inc., Merck Sharp & Dohme Corp., Mimetogen Pharmaceuticals, Novabay Pharmaceuticals, Inc., Novaliq GmbH, Omega Ophthalmics, Pfizer, Inc., Ocuhub, Omeros Corp., Physician Recommended Nutriceuticals, Rapid Pathogen Screening, Inc., Shire, Strathspey Crown LLC, Tearlab Corp., Truvision Systems, Inc., and Versant Ventures. Dr. Kohnen is a consultant to Abbott Medical Optics, Inc., Alcon Laboratories, Inc., Carl Zeiss Meditec AG, Geuder AG, Rayner Intraocular Lenses Ltd., Oculus Optikgeräte GmbH, Schwind eye-tech-solutions GmbH and Co. KG, Tearlab Corp., Thieme Compliance GmbH, and Ziemer Ophthalmic Systems AG; he receives grant support from Abbott Medical Optics, Inc., Alcon Laboratories, Inc., Carl Zeiss Meditec AG, Rayner Intraocular Lenses Ltd., Oculus Optikgeräte GmbH, Schwind eye-tech-solutions GmbH and Co. KG. Dr. Lindstrom is a consultant to Acufocus, Inc., Abbott Medical Optics, Inc., Alcon Laboratories, Inc., Bausch & Lomb, Glaukos Corp., Imprimis Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Tearlab Corp., and Tracey Technologies Inc. Dr. Potvin is a consultant to Alcon Laboratories, Inc., Haag-Streit AG, Imprimis Pharmaceuticals, Inc., Oculus Optikgeräte GmbH, Physiol S.A., and Revision Optics, Inc. Dr. Solomon is a consultant to Alcon Laboratories, Inc., Aquesys, Inc., Clarvista Medical, Glaukos Corp., Icon Bioscience, Inc., Integrity Digital Solutions, Mati Therapeutics, Inc., Octane Visionary VC Fund, Ocuhub, Omeros Corp., Pogotec, Physician Recommended Nutriceuticals, and Versant Ventures. Drs. Sandoval and Tremblay have no financial or proprietary interest in any material or method mentioned.
Publisher Copyright:
© 2016 ASCRS and ESCRS